Experimental and clinical pharmacokinetics of amphotericin B lipid complex

Drugs of Today

Volumn 32, Issue SUPPL. G, 1996, Pages 9-17

  Fromtling, Robert A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; COMPLEX FORMATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHARMACOKINETICS; RABBIT; RAT; REVIEW;

EID: 0029801921     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Gold, W., Stout, H.A., Pagona, J.F., Donovick, R. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Ann 1955-1956, 579-86.
2. Gallis, H.A., Drew, R.H., Pickard. W.W. Ampho-tericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12: 308-29.
3. Lyman, C.A., Walsh, T.J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992, 44: 9-35.
4. Hamilton-Miller, J.M.T. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 1913, 37: 166-9.
5. Hammond, S.M. Biological activity of polyene antibiotics. Prog Med Chem 1977, 14: 105-19.
6. Kinsky,. S.C. Polyene antibiotics. In: Antibiotics. I. Mechanism of Action. D. Gottlieb and P.D. Shaw (Eds.). Springer-Verlag: New York 1967, 122-41.
7. Keller-Schierlein, W. Chemistry of macrolide antibiotics. In: Progress in Chemical Organic Natural Products. W. Herz, H. Grisebach and G.W. Kirby (Eds.). Springer Verlag: New York 1973, 313-460.
8. Mallams, A.K. Antibiotic polyenes. In: Kirk-Othmer Encyclopedia of Chemical Technology, Third Edition, Vol. 3. H.F. Mark et al. (Eds.). John Wiley and Sons: New York 1978, 21-47.
9. Medoff, G., Brajtburg, J., Kobayashi, G.S., Bolard, J. Antifungal agents useful in therapy of systemic fungal infections. Ann Rev Pharmacol Toxicol 1983, 23: 303-30.
10. Schaffner, C.P. Polyene macrolides in clinical practice: Pharmacology and adverse and other effects. In: Macrolide Antibiotics, Chemistry, Biology and Practice. S. Omura (Ed.). Academic Press: New York 1984, 457-507.
11. Kerridge, D. Mode of action of clinically important antifungal drugs. Adv Microbiol Physiol 1986, 27: 1-72.
12. Palacios, J., Serrano, R. Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast. Fed Eur Biochem Soc Lett 1978, 91, 198-201.
13. Medoff, G., Kobayashi, G.S. Strategies in the treatment of systemic fungal infections. New Engl J Med 1980, 302: 145-55.
14. Walsh, T.J. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect 1990, 5: 111-22.
15. Pizzo, P.A., Robichard, K.J., Gill, F.A., Witebsky, F.G. Empirical antibiotic and antibiotic therapy for cancer patients with prolonged fever and granulocytopenia. Amer J Med 1982, 72: 101-11.
16. Walsh, T.J., Pizzo, P.A. Treatment of systemic fungal infections. Recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988, 7: 460-75.
17. Schaffner, C. Amphotericin B derivatives. In: Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. R.A. Fromtling (Ed.). J.R. Prous Science Publishers: Barcelona 1987, 595-618.
18. Szoka, F.C. Jr., Milholland, D., Barza, M. Effect of lipid composition and liposome size on toxicity and in vitro antifungal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother 1987, 31: 421-9.
19. Safety and efficacy of LTI's Amphocil drug product reported at ICAAC meeting. Liposome Technology, Inc., Press Release, Oct 15, 1992.
20. Guo, L.S.S., Fielding, R.M., Lasic, D.D., Hamilton, R.L., Mufson, D. Novel antifungal drug delivery: Stable amphotericin B-cholesteryl sulfate discs. Int J Pharm 1991, 75 (1): 45-64.
21. Fromtling, R.A. Amphotericin B cholesterol sulfate complex. Drugs Fut 1993, 18 (4): 303-6.
22. Fromtling, R. A. Amphotericin B lipid complex. Drugs Fut 1995, 20 (2): 129-34.
23. Wasan, K.M., Grossie, V.B. Jr., López-Berestein, G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous Intralipid infusion. Antimicrob Agents Chemother 1994, 38: 2224-6.
24. Wasan, K.M., Vadiei, K., López-Berestein, G., Luke, D.R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rate. J Infect Dis 1990, 161: 562-6.
25. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R., Fidler, T.J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1983, 42: 1500-2.
26. Mehta, K., López-Berestein, G., Hersh, E.M., Juliano, R.L. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticutoendothelial Soc 1982, 32: 155-64.
27. López-Berestein, G., Mehta, K., Mehta, R., Juliano, R.L., Hersh, E.M. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol 1983, 130: 1500-2.
28. Mehta, R., López-Berestein, G., Hopfer, R., Mills, K., Juliano, R.L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984, 770: 230-4.
29. López-Berestein, G., Mehta, R., Hopfer, R.L. et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983, 147: 939-44.
30. López-Berestein, G., Mehta, R., Hopfer, R., Mehta, K., Hersh, E.M., Juliano, R.L. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv 1983, 1: 37-42.
31. López-Berestein, G., Hopfer, R.L., Mehta, R., Mehta, K., Hersh, E.M., Juliano, R. L. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984, 150: 218-83.
32. López-Berestein, G., McQueen, T., Mehta, K. Protective effect of liposomal amphotericin B against C. albicans infection in mice. Cancer Drug Deliv 1985, 2: 183-9.
33. López-Berestein, G., Fainstein, V., Hopfer, R.L. et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer. J Infect Dis 1985, 151: 704-10.
34. López-Berestein, G. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med 1996, 105: 130-1.
35. Shirkhoda, A., López-Berestein, G., Holbert, J.M., Luna, M.A. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 1986, 159: 349-53.
36. Weber, R.S., López-Berestein, G. Treatment of invasive Aspergillus sinusitis with liposomal amphotericin B. Laryngoscope 1987, 97: 937-41.
37. López-Berestein, G. Liposomes as carriers of antifungal drugs. Ann NY Acad Sci 1988, 544: 590-7.
38. Wiebe, V.J., DeGregorio, M.W. Liposome-encapsulated amphotericin B: A promising new treatment for disseminated fungal infections. Rev Infect Dis 1988, 10: 1097-101.
39. Meunier, F., Schlier, J.P., Coune, A. et al. Amphotericin B encapsulated liposomes administered to cancer patients. Ann NY Acad Sci 1988, 544: 599-610.
40. Amphotericin B lipid complex. The Liposome Company, Inc., Press Release, January 1994.
41. The Liposome Company's amphotericin B lipid complex approved for marketing in Spain. The Liposome Company, Inc., Press Release, October 30, 1995.
42. ® in Spain. The Liposome Company, Inc., Press Release, December 6, 1995.
43. Bindschadler, D.D., Bennett, J.E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969, 120: 427-36.
44. Daneshmend, T.K., Warnock, D.W. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983, 8: 17-42.
45. McCoy, M.J., Ellenberg, J.F., Killiam, A.P. Coccidioidomycosis complicating pregnancy. Amer J Obstet Gynecol 1980, 137: 739-40.
46. Briggs, G.G., Freeman, R.K., Yaffe, S.J. (Eds.). Drugs in Pregnancy and Lactation, 3rd Ed. Williams and Wilkins: Baltimore 1990.
47. Olsen, S.J., Swerdel, M.R., Clark, J.M. et al. Amphotericin B lipid complex: Characteristics and pharmacokinetic studies in laboratory animals. 28th Intersci Conf Antimicrob Agents Chemother (Oct 23-26, Los Angeles) 1988, Abst 315.
48. Clark, J.M., Whitney, R.R., George, R.J. et al. Amphotericin B lipid complex: Efficacy in systemic Candida infections in mice. 28th Intersci Conf Antimicrob Agents Chemother (Oct 23-26, Los Angeles) 1988, Abst 316.
49. Janoff, J.S., Boni, L.T., Popescu, M.C. et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988, 85: 6122-6.
50. Clark, J.M., Whitney, R.R., Olsen, S.J. et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991, 35: 615-21.
51. Allendoerfer, R., Yates, R.R., Sun, S.H., Graybill, J.R. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992, 30: 371-84.
52. Lee, J., Allende, M., Amantea, M. et al. Pharmacokinetics and efficacy of amphotericin B lipid complex (ABLC) against chronic disseminated candidiasis in rabbits. 31st Intersci Conf Antimicrob Agents Chemother (Sept 29 - Oct 2, Chicago) 1991, Abst 579.
53. Perfect, J.R., Wright, K.A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J Antimicrob Chemother 1994, 33: 73-81.
54. Clemons, K.V., Stevens, D.A. Comparative efficacies of amphotericin B lipid complex and amphotericin B desoxycholate suspension against marine blastomycosis. Antimicrob Agents Chemother 1991, 35: 2144-6.
55. Cicogna, C., Bernard, E.M., White, M.H., Tong, W.P., Gordon, D.S., Armstrong, D. Prevention of experimental pulmonary aspergillosis with aerosol amphotericin B lipid complex (ABLC). 95th Gen Meet Amer Soc Microbiol (May 21-25, Washington, DC) 1995, Abst F-123.
56. ™): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993, 3: 451-71.
57. Kan, V., Bennett, J., Armantea, M. et al. Comparative safety and pharmacokinetic study of amphotericin B lipid complex (ABLC) and amphotericin B desoxycholate (AB) in healthy young male volunteers. 30th Intersci Conf Antimicrob Agents Chemother (Oct 21-24, Atlanta) 1990, Abst 4.
58. Kan, V., Bennett, J., Amantea, M.A. et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and ampho-tericin B desoxycholate in healthy male volunteers. J Infect Dis 1991, 164; 418-21.
59. Atkinson, A.J., Bennett, J.E. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978, 13: 271-6.
60. Grasela, D., Echevarria, J., Summerill, R. et al. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC) or Fungizone (FZ) in adults with mucocutaneous leishmaniasis. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 1439.
61. Oravcova, E., Mistrik, M., Sakalova, A. et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: Report of efficacy and safety in 20 patients. Chemotherapy 1995, 41: 473-6.